How to combine semaglutide, tirzepatide, and retatrutide with other peptides for enhanced fat loss, lean mass preservation, GI protection, and recovery. Protocols, rationale, and honest evidence ratings.
GLP-1 receptor agonists are the most effective weight loss compounds available in research, but they have three well-documented limitations that other peptides can directly address:
Nausea, vomiting, and gastroparesis affect 30–40% of users during dose escalation. BPC-157's gut-protective effects offer a targeted solution.
25–35% of total weight lost on GLP-1 peptides can be lean mass, not fat. Growth hormone secretagogues help preserve muscle during caloric restriction.
Most users plateau at 15–25% weight loss. Complementary fat oxidation compounds working through different receptors may extend progress.
GLP-1 peptides slow gastric emptying and can cause significant nausea, vomiting, and gastroparesis — especially during dose escalation. BPC-157's cytoprotective effects on gastric mucosa and its ability to reduce intestinal permeability may directly counteract these GI side effects.
BPC-157: 250–500mcg twice daily (morning and evening), subcutaneous. Begin concurrently with GLP-1 initiation or at first sign of GI symptoms. Run for 4–8 weeks during dose escalation phase.
Mechanistic rationale strong; no direct combination studies
No interaction data; introduce BPC-157 first to establish baseline tolerability
Aggressive caloric restriction from GLP-1 peptides can result in 25–35% of total weight loss coming from lean mass. Growth hormone secretagogues stimulate endogenous GH release, promoting muscle protein synthesis and fat oxidation. This stack aims to shift the fat:muscle loss ratio in favor of fat.
Sermorelin: 200–300mcg before bed, subcutaneous. OR Ipamorelin/CJC-1295: 200mcg/200mcg before bed. Run continuously alongside GLP-1 therapy. Resistance training is essential to maximize lean mass preservation.
Strong mechanistic rationale; each compound individually well-studied; no combination RCTs
GH secretagogues may slightly blunt insulin sensitivity — monitor if using with diabetes medications
AOD-9604 is a modified fragment of human growth hormone (hGH 176-191) that stimulates fat oxidation through beta-3 adrenergic receptors without the insulin-desensitizing effects of full HGH. It works through a completely different mechanism than GLP-1 peptides, potentially providing additive fat loss.
AOD-9604: 300mcg once daily, subcutaneous, on an empty stomach. Can be run continuously alongside GLP-1 therapy. Some protocols use 150mcg twice daily instead.
Moderate; AOD-9604 Phase 2 data positive for fat loss; no combination studies
AOD-9604 is not FDA-approved; limited human safety data beyond Phase 2 trials
Rapid weight loss from GLP-1 peptides can increase joint stress as body mechanics change, and some users report increased injury susceptibility during aggressive weight loss phases. TB-500's systemic tissue repair and anti-inflammatory effects may help maintain connective tissue integrity during rapid body composition changes.
TB-500: 2.5–5mg twice weekly for 4–6 weeks (loading phase), then 2.5mg once weekly (maintenance). Subcutaneous injection.
Weak for this specific combination; individual TB-500 evidence is animal-based
This is the most speculative stack on this list; TB-500 is primarily studied for acute injury, not prophylactic use
GLP-1 peptides have demonstrated cardiovascular protective effects (SELECT trial: 20% reduction in MACE). Epithalon's proposed mechanisms — telomere elongation, antioxidant activity, circadian rhythm regulation — are complementary to GLP-1's metabolic and cardiovascular benefits for a comprehensive longevity protocol.
Epithalon: 5–10mg daily for 10–20 day cycles, 2–4 times per year. Subcutaneous or intranasal. Run independently of GLP-1 dosing schedule.
Weak for combination; each compound individually has limited human data
Epithalon human data is very limited; this is a highly speculative combination
Start with your GLP-1 compound and establish tolerability before adding anything else. Wait 2–4 weeks before introducing a second compound.
When adding a new compound to an existing stack, start at the minimum dose and titrate up. This makes it easier to identify which compound is responsible for any adverse effects.
Track weight, body composition, energy, GI symptoms, sleep quality, and any adverse effects. This data is essential for optimizing the stack and identifying problems early.
Beyond 3 compounds, the interaction complexity increases significantly and it becomes impossible to attribute effects or side effects to specific compounds.
No combination stacking studies exist. All protocols on this page are based on individual compound data and mechanistic rationale, not clinical evidence for the combinations.
GLP-1 peptides are most effective alongside caloric awareness and resistance training. Stacking additional compounds does not substitute for these fundamentals.
Purgo Labs carries all compounds mentioned in this guide — third-party tested, batch-verified.
View All Compounds at Purgo LabsUse code HEALTH for 15% off
BPC-157 is commonly stacked with GLP-1 peptides to address GI side effects. BPC-157's cytoprotective effects on gastric mucosa may reduce nausea, vomiting, and gastroparesis associated with semaglutide. There is no known interaction between the two compounds. Typical protocol: BPC-157 250–500mcg twice daily during the first 4–8 weeks of GLP-1 use.
Sermorelin or ipamorelin/CJC-1295 are the most commonly used stacks with tirzepatide for body composition. GLP-1 peptides cause significant weight loss but can also reduce lean mass. Growth hormone secretagogues help preserve muscle mass during aggressive caloric restriction. AOD-9604 is also used for complementary fat loss via a different mechanism.
No large-scale safety data exists for peptide stacking combinations. Individual compounds have their own safety profiles, but interaction data is essentially absent. The general principle is to introduce one compound at a time, monitor for adverse effects, and avoid stacking more than 2–3 compounds simultaneously.
Yes — the same rationale applies as with semaglutide and tirzepatide. Retatrutide's GI side effects (nausea, vomiting, diarrhea) are the primary tolerability concern, and BPC-157's gut-protective effects may reduce their severity. This is a logical stack but has no published research supporting it specifically.
The most evidence-supported weight loss stack is a GLP-1 peptide (semaglutide, tirzepatide, or retatrutide) as the primary agent, with sermorelin or ipamorelin/CJC-1295 to preserve lean mass, and BPC-157 to manage GI side effects. AOD-9604 can be added for complementary fat oxidation via a different pathway.
Timing relative to GLP-1 injections is not critical since BPC-157 works through different receptors. Most protocols use BPC-157 in the morning and evening regardless of when the weekly GLP-1 injection is administered. The key is consistency rather than precise timing relative to the GLP-1 dose.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.